文献速递慢性肾脏病血液净化与透析

老年糖尿病患者SGLT2抑制剂与DPP4抑制剂的肾脏结局比较

Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

基于全国理赔数据库的倾向性评分匹配研究,纳入6354例≥60岁糖尿病新用药者,比较SGLT2抑制剂与DPP4抑制剂对eGFR变化的影响。结果显示SGLT2抑制剂组eGFR下降更慢,且eGFR下降≥20%、≥30%、≥40%的风险显著更低。提示老年糖尿病患者使用SGLT2抑制剂可能对肾脏结局有优势。

要点

  • 老年糖尿病患者中,SGLT2抑制剂较DPP4抑制剂延缓eGFR下降。
  • SGLT2抑制剂组eGFR下降≥20%、≥30%、≥40%的风险显著更低。
  • 亚组分析(年龄、性别、BMI、HbA1c、RAS抑制剂、基线eGFR)结果一致。

核心结论

  • 在≥60岁糖尿病患者中,SGLT2抑制剂较DPP4抑制剂使eGFR下降更慢,提示SGLT2抑制剂对老年糖尿病患者肾脏结局可能有益。

研究设计与样本

  • 基于全国理赔数据库的回顾性队列研究,纳入6354例≥60岁糖尿病新起始SGLT2抑制剂或DPP4抑制剂治疗者,采用1:4倾向性评分匹配比较eGFR变化。

主要发现

  • 匹配后纳入1271例SGLT2抑制剂使用者和5083例DPP4抑制剂使用者,中位年龄68岁(IQR 65-70),男性60.4%,中位eGFR 69.0 ml/min/1.73 m2(IQR 59.1-79.0),中位HbA1c 6.9%(IQR 6.5-7.4)。
  • SGLT2抑制剂组eGFR年下降速率为-0.97 ml/min/1.73 m2/年(95% CI -1.24至-0.70),DPP4抑制剂组为-1.83 ml/min/1.73 m2/年(95% CI -1.97至-1.69),交互作用P<.001。
  • 基于年龄、性别、BMI、HbA1c水平、RAS抑制剂使用和基线eGFR的亚组分析结果一致。
  • SGLT2抑制剂组eGFR较基线下降≥20%、≥30%和≥40%的风险显著低于DPP4抑制剂组。

临床怎么用

  • 对于≥60岁糖尿病患者,选择SGLT2抑制剂可能有助于延缓eGFR下降,尤其适用于关注肾脏结局的老年患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While the kidney-protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors have attracted much attention, there are limited real-world clinical data examining the effects of SGLT2 inhibitors on kidney function in older individuals. We aimed to compare the kidney outcomes between SGLT2 inhibitor and dipeptidyl peptidase 4 (DPP4) inhibitor use in older adults with diabetes. METHODS: Using a nationwide claims database, we studied 6354 older adults (≥60 years of age) who had diabetes and were newly initiated on SGLT2 inhibitors or DPP4 inhibitors. A 1:4 propensity score matching algorithm was used to compare changes in estimated glomerular filtration rate (eGFR) between SGLT2 inhibitor and DPP4 inhibitor users. The primary outcome was a decrease in the rate of eGFR, which was obtained using a linear mixed-effects model with an unstructured covariance. RESULTS: Following propensity score matching, 6354 individuals including 1271 SGLT2 inhibitor users and 5083 DPP4 inhibitor users {median age 68 years [interquartile range (IQR) 65-70], male 60.4%, median eGFR 69.0 ml/min/1.73 m2 [IQR 59.1-79.0], median haemoglobin A1c [HbA1c] 6.9% [IQR 6.5-7.4]} were analysed. SGLT2 inhibitor users had a slower eGFR decline than did DPP4 inhibitor users [-0.97 ml/min/1.73 m2/year (95% CI -1.24 to -0.70) versus -1.83 ml/min/1.73 m2/year (95% CI -1.97 to -1.69); P for interaction <.001]. This finding remained consistent across subgroups based on age, sex, body mass index, HbA1c level, renin-angiotensin system inhibitor use and baseline eGFR. Additionally, the risk of a ≥20%, ≥30% and ≥40% decrease in eGFR from baseline was significantly lower in SGLT2 inhibitor users than in DPP4 inhibitor users. CONCLUSIONS: Our analysis, utilizing a nationwide epidemiological dataset, demonstrated that the decrease in eGFR was slower in individuals ≥60 years of age with diabetes who were prescribed SGLT2 inhibitors compared with those prescribed DPP4 inhibitors, suggesting a potential advantage of SGLT2 inhibitors for kidney outcomes even in older individuals with diabetes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Suzuki Y, Kaneko H, Okada A, et al. Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes. Nephrol Dial Transplant. 2025. PMID: 38991990. doi:10.1093/ndt/gfae158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。